GlassScriptPhysician profile
Charles L Clark
NPI 1912158627
$1,838.33
in general payments reported to CMS, 2019-2025
17 companies · $87.00 in 2025
The $87.00 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $71.02 · 2021: $156 · 2022: $1,104 · 2023: $184 · 2024: $47.38 · 2025: $87.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $921.35 | 2022 | |
| Abbvie INC. | $146.28 | 2019-2025 | Ozurdex |
| Alcon Vision LLC | $104.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $92.11 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $89.81 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.86 | 2019 | |
| Biotissue Holdings INC. | $83.65 | 2020-2021 | |
| Coherus Oncology, INC. | $81.76 | 2023-2024 | |
| Apellis Pharmaceuticals, INC. | $65.21 | 2023 | Syfovre |
| Horizon Therapeutics Plc | $43.18 | 2021-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $28.00 | 2024 | Eylea, Eylea Hd |
| Ani Pharmaceuticals, INC. | $24.55 | 2025 | Iluvien |
| Astellas Pharma US INC | $22.48 | 2025 | Izervay |
| Allergan, INC. | $17.41 | 2020 | |
| Genentech USA, INC. | $15.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $13.94 | 2023 | Iluvien |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.